News Agency
The Times Real Estate

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

  • Written by PR Newswire
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F

Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Feb. 13, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global...

Read more: Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical...

How Website Speed Matters for Ecommerce Business?

In the competitive landscape of eCommerce, where every second counts, website speed is a critical factor that can make or break your business. For eCommerce businesses in Melbourne, the importance of a fast-loading website extends beyond mere aesthetics; it directly... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion